1. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany
- Author
-
Abraham, S., Haufe, E., Harder, I., Heratizadeh, A., Kleinheinz, A., Wollenberg, A., Weisshaar, E., Augustin, M., Wiemers, F., Zink, A., Biedermann, T., von Kiedrowski, R., Hilgers, M., Worm, M., Pawlak, M., Sticherling, M., Fell, I., Handrick, C., Schäkel, K., Staubach, P., Asmussen, A., Schwarz, B., Bell, M., Neubert, K., Effendy, I., Bieber, T., Homey, B., Gerlach, B., Tchitcherina, E., Stahl, M., Schwichtenberg, U., Rossbacher, J., Buck, P., Mempel, M., Beissert, S., Werfel, T., Weidinger, S., Schmitt, J., and TREATgermany study group
- Subjects
medicine.medical_specialty ,business.industry ,Eczema ,MEDLINE ,Dermatology ,Antibodies, Monoclonal, Humanized ,Dupilumab ,language.human_language ,Dermatitis, Atopic ,German ,Family medicine ,language ,Humans ,Medicine ,Registries ,National registry ,business ,Routine care - Abstract
The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.1,2 Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.3-5 Real world evidence is now needed to evaluate its effectiveness and safety in routine care.
- Published
- 2020
- Full Text
- View/download PDF